Dexmedetomidine vs. Diprivan in Cardiac Surgery

Authors

Christopher Costea, Lynchburg UniversityFollow

Specialty

Cardiothoracic Surgery

Advisor

Dr. Laura Witte

Abstract

Purpose: The purpose of this review article is to analyze how the use of dexmedetomidine can be beneficial in Cardiac Surgery when compared to diprivan.

Method: For the initial search was performed using the following keywords: “dexmedetomidine” AND “Propofol” AND “cardiac surgery” AND “postoperative” AND “extubation” OR “heart surgery”. Searches were performed on PubMed, Cochrane Library and Medline databases. Of these databases around forty-fiver articles met my search criteria. I narrowed the results by specifically added the key word “mortality”. This further narrowed down my search. Ten articles became the basis for my paper.

Results: There is an abundance of data looking at dexmedetomidine usage in Cardiac Surgery with evidence showing its benefits. Dexmedetomidine has been shown to significantly lower overall mortality in post-operative cardiac surgery patients when compared to Propofol. One study looked at 1,134 patients who underwent Coronary Artery Bypass Surgery Graft (CABG), and CABG plus valvular and/or other procedures were included. 568 received intravenous dexmedetomidine infusion, and 566 did not.

Conclusion: Dexmedetomidine appears to be associated with decreased mortality in Cardiac Surgery patients when compared to Propofol in the studies reviewed. The research demonstrates there is decreased ventilatory times, decreased adverse events, and decreased episodes of delirium post operatively with dexmedetomidine.

Recommended Citation

Costea C. Dexmedetomidine vs. Diprivan in Cardiac Surgery. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2021; 3(3).